AstraZeneca commits $100M to China R&D
Anglo-Swedish drug major AstraZeneca has announced its intention to invest $100.0 million in R&D in China over the next three years, saying that this will focus on the benefit and value of innovative medicines for Chinese patients.
The prime focus of this program will be the establishment of the AstraZeneca Innovation Center China. The company says it has initiated a comprehensive search for an appropriate location for the Center, which will be operational by the end of 2009. It will focus on translational science by developing knowledge about Chinese patients, biomarkers and genetics, the firm notes, adding that the initial therapeutic area will be cancer, which is a major cause of death in China.
Looking to expand collaborations
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze